Study: Dapagliflozin plus metformin works well for Type 2 diabetes

09/26/2010 | Reuters

The combination of AstraZeneca and Bristol-Myers Squibb's dapagliflozin and metformin, a standard diabetes drug, reduced body weight and the incidence of hypoglycemic events more than glipizide plus metformin during a late-stage study involving Type 2 diabetics. Both drug combinations proved effective in lowering patients' hemoglobin HbA1c level within 52 weeks of treatment.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Manager/Sr. Compliance Manager- Auditing
Genentech
South San Francisco, CA
Director of Program Development
AdvaMed
Washington DC, DC
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL